1216744-19-2 Usage
Description
1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate is a complex organic compound with a unique chemical structure. It is characterized by the presence of a glycinate group, which is a derivative of glycine, an amino acid. The molecule also features a 1,1-dimethylethyl group, a 4-chlorophenylmethyl group, and a 5-nitro-2-thienylmethyl group, which contribute to its specific properties and potential applications.
Uses
1. Used in Pharmaceutical Applications:
1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate is used as a synthetic ligand for targeting specific receptors in the nuclear receptor superfamily. Its chemical structure allows it to mimic the action of certain natural ligands, such as heme, and modulate the expression of target genes involved in various biological processes.
2. Used in Drug Development:
In the pharmaceutical industry, 1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate can be utilized as a starting material or a key intermediate in the synthesis of novel drugs. Its unique structure and functional groups make it a promising candidate for the development of new therapeutic agents with specific biological activities.
3. Used in Chemical Research:
Due to its complex structure and diverse functional groups, 1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate can also be employed in chemical research for studying various reaction mechanisms, exploring new synthetic routes, and understanding the relationship between chemical structure and biological activity.
4. Used in Drug Delivery Systems:
Similar to gallotannin, 1,1-Dimethylethyl-N-[(4-chlorophenyl)methyl]-N-[(5-nitro-2-thienyl)methyl])glycinate can potentially be incorporated into drug delivery systems to improve its bioavailability, targeting, and therapeutic efficacy. The development of novel carriers, such as organic and metallic nanoparticles, can enhance the delivery of this compound to specific cells or tissues, thereby increasing its potential applications in various industries.
Biochem/physiol Actions
GSK4112 is a rev-erbα, (orphan nuclear receptor NR1D1) agonist, the first agent able to reset the circadian clock in a phase-dependent manner. Rev-erbα impacts the precision of the circadian clock by repressing target gene activities with the help of a nuclear receptor co-repressor complex (NCoR) and HDAC3. GSK4112 competes with heme (rev-erb′s natural ligand) and enhances co-repressor complex recruitment and thus, repression of transcription. suggests that pharmacological modulation through Rev-erb may provide new routes to treat metabolic diseases, especially disorders of adipogenesis regulated by rev-erba.
Check Digit Verification of cas no
The CAS Registry Mumber 1216744-19-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,6,7,4 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1216744-19:
(9*1)+(8*2)+(7*1)+(6*6)+(5*7)+(4*4)+(3*4)+(2*1)+(1*9)=142
142 % 10 = 2
So 1216744-19-2 is a valid CAS Registry Number.
1216744-19-2Relevant articles and documents
Optimized chemical probes for REV-ERBα
Trump, Ryan P.,Bresciani, Stefano,Cooper, Anthony W. J.,Tellam, James P.,Wojno, Justyna,Blaikley, John,Orband-Miller, Lisa A.,Kashatus, Jennifer A.,Boudjelal, Mohamed,Dawson, Helen C.,Loudon, Andrew,Ray, David,Grant, Daniel,Farrow, Stuart N.,Willson, Timothy M.,Tomkinson, Nicholas C. O.
, p. 4729 - 4737 (2013/07/19)
REV-ERBα has emerged as an important target for regulation of circadian rhythm and its associated physiology. Herein, we report on the optimization of a series of REV-ERBα agonists based on GSK4112 (1) for potency, selectivity, and bioavailability.(1) Potent REV-ERBα agonists 4, 10, 16, and 23 are detailed for their ability to suppress BMAL and IL-6 expression from human cells while also demonstrating excellent selectivity over LXRα. Amine 4 demonstrated in vivo bioavailability after either iv or oral dosing.
